You are here » Home » Companies » Company Overview » Cipla Ltd

Cipla Ltd.

BSE: 500087 Sector: Health care
NSE: CIPLA ISIN Code: INE059A01026
BSE 10:21 | 25 Sep 652.65 6.55
(1.01%)
OPEN

646.00

HIGH

654.25

LOW

645.00

NSE 10:09 | 25 Sep 648.95 3.35
(0.52%)
OPEN

644.00

HIGH

654.70

LOW

643.00

OPEN 646.00
PREVIOUS CLOSE 646.10
VOLUME 21662
52-Week high 678.00
52-Week low 508.10
P/E 31.67
Mkt Cap.(Rs cr) 52,555
Buy Price 651.40
Buy Qty 217.00
Sell Price 652.25
Sell Qty 190.00
OPEN 646.00
CLOSE 646.10
VOLUME 21662
52-Week high 678.00
52-Week low 508.10
P/E 31.67
Mkt Cap.(Rs cr) 52,555
Buy Price 651.40
Buy Qty 217.00
Sell Price 652.25
Sell Qty 190.00

Cipla Ltd. (CIPLA) - Chairman Speech

Company chairman speech

We have come a long way over the past 82 years. All of us shareholders of Ciplashould be proud of what our company has achieved. However one important aspect hasremained unchanged. This is our commitment to access to medicines.

Dear Shareholders

It has been an eventful year for the pharma industry both in India andinternationally. Cipla has had a good year as is reflected in this Annual Report.

Continuity and Change

Over the past 58 years I have seen the Indian pharma industry go through many diversechanges particularly in India. In the pre-1972 period we were under a restrictive patentregime. Subsequently the indigenous pharma industry went through a golden era till 2005.In recent years there has been a major shift in the working of the industry. This hasinvolved many joint ventures partnerships in and out licensing mergers andacquisitions. Overall there has been considerable consolidation. Cipla has very much beena part of this constantly-evolving pharma landscape. Around the mid-1990s our domesticrevenue was around 90% of our sales and today it is 39%. This shift in our businessprofile has been necessary and we now partner many companies globally. The process ofprofessionalisation of our management is now complete and we have expanded to become atruly international pharmaceutical company. We have come a long way over the past 82years. All of us shareholders of Cipla should be proud of what our company has achieved.However one important aspect has remained unchanged. This is our commitment to access tomedicines at affordable prices and hence our continued support to patients thereby savinglives. Cipla has developed many newer business strategies to improve its portfolio. Youcan rest assured that we will do whatever is required to ensure our unwavering commitmentto patients in need.

Our Work Beyond Numbers

Just as the pharma industry responds to change so also should governments around theworld. Debates around drug pricing intellectual property the Goods and Services Tax inIndia the National Health Protection Mission and price erosion in the US have been inthe news. Cipla is closely monitoring ongoing

I am happy to see that we are on track. Many strategic decisions taken over the pastfew years are coming to fruition.

developments and will contribute in every possible way to improvement in healthcare. Itis in this overall scenario that we must carefully study the credibility andsustainability of our Company. A few years ago we had planned that 2017 would be a yearof streamlining Cipla's business model and identifying our core businesses and strengths.We then planned for 2018 to be a year of consolidation. From 2019 onwards we believe thatwe can capitalise on the core foundation that we have built on. I am happy to see that weare on track. Many strategic decisions taken over the past few years are coming tofruition. I am particularly pleased that our emphasis on R&D continues unabated. Wehave now developed a unique breath-actuated inhaler with a dose counter calledSynchrobreathe for the benefit of asthma patients. Cipla is gradually building itsrespiratory franchise in regulated markets. We have targeted a major expansion of ourpresence in the USA. It has involved many generic drug filings and this momentum willcontinue. Along with this we plan to expand beyond generics into selected and nicheSpecialty products. Apart from this the Cipla Global Access program is very special forthe company as this involves business with a humanitarian vision. Your Company receivedthe world's first WHO approval for its product Q-TIB a prophylaxis against TB in HIV/AIDSpatients. PEPFAR has approved our product lopinavir/ritonavir oral pellets for paediatricuse in HIV/AIDS. For malaria Cipla has introduced its rectal artesunate suppository to beadministered to children in emergency situations. As a scientist first and foremost tome the above captures the essence of our theme in this report – innovation for thebenefit of patients.

The Cipla Palliative Care Centre in Pune has now completed 20 years of service toterminally ill cancer patients and over 14000 patients have been cared for. I amcertainly happy that the company continues to follow this path of community and socialsupport.

What Next for Pharma

Healthcare and disease patterns around the world are changing – non-communicableand lifestyle diseases are now increasingly taking centre-stage in disease burden studies.You will be interested to know that Cipla is committed and fully associated with the nextmajor medical hurdle facing the world namely Anti-Microbial Resistance (AMR). Thisinvolves a major thrust to control the misuse and overuse of antibiotics. Immuno-therapystem-cell technology biological and vaccine products diagnostics tele-medicinedigitalisation and artificial intelligence are all areas that will define us as anindustry in the next twenty years. The pharma industry is in so many ways a custodian ofthe healthcare needs of the world and your Company will do whatever best possible forhealthcare in the years ahead. As always my heartfelt thanks to all of you for your faithand trust in us. Your Board and Management Council will continue to ensure that ourpurpose of ‘Caring for Life' continues to underpin our business even as we delivervalue.

Warm Regards

Y.K. Hamied

Chairman